Structure Therapeutics Inc.(GPCR)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
GPCR Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Structure Therapeutics Inc. (GPCR), a Healthcare sector company. GPCR is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Structure Therapeutics Inc. reports net income of $-106.2M, free cash flow of $-120.2M. Top institutional holders of GPCR by reported 13-F value include FMR, WELLINGTON MANAGEMENT GROUP LLP, Avoro Capital Advisors, based on the most recent SEC filings. GPCR trades on the Nasdaq exchange and files with the SEC under CIK 1888886. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GPCR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Structure Therapeutics Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-106.2M
Free Cash Flow
Q2 2026
$-120.2M
ROIC
Q2 2026
-35.0%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-15.2% YoYOperating Income
-11.6% YoYEPS (Diluted)
-2.6% YoYTotal Assets
+75.3% YoYOp. Cash Flow
-90.5% YoYFree Cash Flow
-91.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Income | $-141.2M -15.2% | $-122.5M -36.7% | $-89.6M -74.6% | $-51.3M | — |
| Operating Income | $-176.6M -11.6% | $-158.2M -54.0% | $-102.8M -95.5% | $-52.6M | — |
| EPS (Diluted) | $-0.80 -2.6% | $-0.78 +3.7% | $-0.81 -61.7% | $-0.50 | — |
| Total Assets | $1.58B +75.3% | $903.3M +87.4% | $482.0M +392.6% | $97.8M | — |
| Operating Cash Flow | $-222.2M -90.5% | $-116.6M -46.7% | $-79.5M -72.4% | $-46.1M | — |
| Free Cash Flow | $-225.8M -91.5% | $-117.9M -44.4% | $-81.7M -76.5% | $-46.3M | — |
Get alerted when GPCR's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Structure Therapeutics Inc. including:
Top Institutional Holders of GPCR
FMR LLC
$419.2M7,810,306 shWELLINGTON MANAGEMENT GROUP LLP
$396.1M7,379,433 shAvoro Capital Advisors LLC
$351.8M6,555,555 shJupiter Topco LLC
$279.3M5,204,212 shDeep Track Capital, LP
$254.4M4,740,072 shBVF INC/IL
$180.7M3,366,823 shMORGAN STANLEY
$150.6M2,806,640 shORBIMED ADVISORS LLC
$118.6M2,209,400 shPRINCIPAL FINANCIAL GROUP INC
$94.1M1,752,753 shAMERICAN CENTURY COMPANIES INC
$90.3M1,682,179 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $419.2M | 7,810,306 |
| WELLINGTON MANAGEMENT GROUP LLP | $396.1M | 7,379,433 |
| Avoro Capital Advisors LLC | $351.8M | 6,555,555 |
| Jupiter Topco LLC | $279.3M | 5,204,212 |
| Deep Track Capital, LP | $254.4M | 4,740,072 |
| BVF INC/IL | $180.7M | 3,366,823 |
| MORGAN STANLEY | $150.6M | 2,806,640 |
| ORBIMED ADVISORS LLC | $118.6M | 2,209,400 |
| PRINCIPAL FINANCIAL GROUP INC | $94.1M | 1,752,753 |
| AMERICAN CENTURY COMPANIES INC | $90.3M | 1,682,179 |
More Healthcare Companies
View all Healthcare →Put GPCR on your watchlist
Track score changes the day Structure Therapeutics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is GPCR a good stock to buy?
13F Pro's AI-powered analysis of Structure Therapeutics Inc. (GPCR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GPCR are available on the GPCR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. GPCR is classified as a mid company.
Which hedge funds own GPCR?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GPCR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Structure Therapeutics Inc.'s investment landscape.